Full-Time

IT Support Services Technician 1

Updated on 8/1/2026

Inotiv

Inotiv

1,001-5,000 employees

Global CRO for life sciences research

Compensation Overview

$25 - $27/hr

West Lafayette, IN, USA

Remote

Occasional travel to other company locations may be required; 24-hour emergency recall may include weekends and nights.

Category
Customer Experience & Support (1)
IT & Security (1)
Required Skills
Microsoft Windows
Operating Systems
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Inotiv

See people who can refer or advise you

Requirements
  • A bachelor's degree in computer science, information technology, or a related field is preferred.
  • IT certifications such as CompTIA A+, Microsoft Certified Desktop Support Technician, or equivalent are a plus.
  • Proven experience in a similar IT service desk or technical support role is required.
  • Strong knowledge of Windows operating systems is required.
  • Familiarity with common software applications, office productivity tools, and collaboration platforms is required.
  • The ability to troubleshoot and resolve technical issues independently is required.
  • The ability to read, write, speak, and understand English is required.
  • The position requires frequent walking, standing for extended periods, sitting for extended periods, talking for extended periods, carrying items weighing up to 25 pounds, reaching while standing, and general repetitive motions.
Responsibilities
  • Provide first-line support to end-users via phone, email, or in person for hardware, software, network connectivity, and other IT-related concerns.
  • Document all support interactions, including the problem, troubleshooting steps, and applied resolution.
  • Diagnose and resolve technical issues with desktops, laptops, printers, and other end-user devices.
  • Troubleshoot software applications, operating systems, and peripheral equipment and implement effective solutions.
  • Log and prioritize user-reported incidents and ensure timely resolution within established service level agreements.
  • Escalate complex issues to higher-level support teams and follow up on escalated issues through resolution.
  • Assist users with understanding and using software applications and IT services.
  • Provide guidance on computer-use best practices, security awareness, and data protection.
  • Monitor IT systems for potential issues and proactively address them to prevent service disruptions.
  • Maintain current documentation of IT systems, procedures, and troubleshooting steps.
  • Contribute to the knowledge base to improve problem resolution and IT service desk effectiveness.
  • Work collaboratively with other IT teams to resolve complex issues and contribute to continuous improvement initiatives.
  • Participate in team meetings and training sessions regarding new technologies and best practices.
  • Provide customer service-oriented end-user technical support to computer users at all company locations.
  • Provide technical expertise and individualized personal-computer training to company staff.
  • Build and maintain hardware and software inventories under management direction.
  • Maintain confidential information.
  • Support and participate in other company initiatives as directed by management.
  • Perform other assigned duties.
  • Provide emergency response support when recalled, including possible weekend and nighttime operations.
Desired Qualifications
  • Excellent communication and interpersonal skills.
  • CompTIA A+ certification.
  • Microsoft Certified Desktop Support Technician certification or equivalent certification.

Inotiv provides contract research services across drug discovery, preclinical testing, analytical testing, and related areas for the pharmaceutical and biotech industries. Its offerings combine analytical chemistry, preclinical research, and access to a broad set of research models to generate data and prepare regulatory-compliant documentation that supports drug development, safety testing, and medical device evaluation. The company differentiates itself through an integrated CRO model that pairs BASi’s analytical capabilities, Seventh Wave’s preclinical work, and Envigo’s research models in one end-to-end service. Its goal is to be a global partner for drug discovery, safety assessment, and product development by delivering scalable research services and regulatory-grade data to biopharma and medical device customers.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

West Lafayette, Indiana

Founded

1974

Get referred to Inotiv

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pre-packaged Chapter 11 with $65 million financing can stabilize liquidity.
  • A unified Inotiv brand simplifies selling bundled nonclinical and analytical services.
  • Integrated services and research models support cross-selling to pharmaceutical and biotech clients.

What critics are saying

  • Chapter 11 can dilute equity and transfer control to lenders.
  • Envigo-related animal-rights scrutiny threatens customer retention and regulatory approvals.
  • Debt restructuring dependence leaves limited flexibility for capex and acquisitions.

What makes Inotiv unique

  • Founded in 1974 as BASi, combining GLP bioanalysis with preclinical CRO services.
  • The 2021 Envigo acquisition added research models to Inotiv's integrated platform.
  • BASi Research Products preserves an instruments and consumables channel alongside services.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Pension

Life Insurance

Wellbeing Program

Paid Time Off

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Stock Options

Company Equity

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Parental Leave

Paid Holidays

Short-term Disability

Long-term Disability

Dental Insurance

Vision Insurance

Phone/Internet Stipend

Home Office Stipend

Paid Vacation

Paid Sick Leave

Flexible Benefits Scheme

Employee Assistance Program

Private Health Insurance

Health cash plan

Retail discounts

Education allowance

Tuition Reimbursement

Meal Benefits

Adoption Assistance

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Pryor Cashman
Jun 22nd, 2026
Pryor Cashman represents Acquiom Agency Services as DIP Agent and administrative and collateral in Inotiv Chapter 11 cases.

Pryor Cashman represents Acquiom Agency Services as DIP Agent and administrative and collateral in Inotiv Chapter 11 cases. Pryor Cashman has been engaged as counsel to Acquiom Agency Services LLC ("Acquiom"), in its roles as (i) DIP Agent for the Debtor-in-Possession Loan Credit Agreement, and (ii) administrative and collateral agent under the Prepetition First Lien Credit Agreement in the Chapter 11 bankruptcy cases of Inotiv, Inc. ("Inotiv") and its affiliated debtors. Inotiv is a contract research organization that provides drug discovery and development services to the pharmaceutical and medical device industries. On June 3, 2026, Inotiv and certain of its affiliates filed for bankruptcy protection in the United States Bankruptcy Court for the Southern District of Texas. The Pryor Cashman team representing Acquiom includes Partner Seth H. Lieberman, Chair of the Bankruptcy, Reorganization, and Creditors' Rights Group and Co-Chair of the Corporate Trust Practice; Partner Patrick Sibley, Co-Chair of the Corporate Trust Practice; Partner David W. Smith; Counsels Arsala Kidwai and Andrew S. Richmond; and Associate Daniel Brenner.seth Related people. Related services & industries. Firm Highlights Slide 1 of 10

Inotiv
Jun 3rd, 2026
Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

Receives commitments for $65 million in new money financing to support ongoing business operations Recapitalization effectuated through a pre-packaged plan of reorganization on an expedited basis Transaction is supported by substantially all of the Company’s existing lenders Normal business operations will continue seamlessly with no impact on vendors and suppliers Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it has entered into a Restructuring Support Agreement (“RSA”) with its Prepetition First Lien Lenders and Ad Hoc Group of Noteholders, constituting substantially all of its junior creditors, to implement a comprehensive recapitalization transaction that will strengthen its capital structure. To implement the transaction, Inotiv has filed a voluntary, prepackaged chapter

Stock Titan
Dec 11th, 2025
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

Inotiv partners with VUGENE to advance ai-driven drug Discovery and bioinformatics capabilities. Rhea-AI summary. Inotiv (NASDAQ: NOTV) announced a strategic collaboration with VUGENE on December 11, 2025 to integrate VUGENE's cloud-based AI/ML multi-omics bioinformatics platform into Inotiv's Discovery & Translational Sciences Division. The partnership aims to accelerate AI-assisted drug discovery by improving interpretation of epigenomic, proteomic, and other molecular datasets to better predict drug efficacy and safety in early-stage research. Inotiv said the integration will enable more efficient, data-driven decision making for client discovery programs, while VUGENE expects broader application of its computational technologies in real-world research settings. News market reaction 1 alert. On the day this news was published, NOTV declined 4.48%, reflecting a moderate negative market reaction. Data tracked by StockTitan Argus on the day of publication. Technical Shares at 0.8414 are trading below the 200-day MA of 1.87 and 87.02% under the 52-week high. Peers on Argus 1 down. Sector peers show mixed moves, with ADVB down 9.61% and others modestly up or down. With only one peer in momentum and no shared news, the AI-focused partnership appears company-specific rather than part of a sector-wide move. Historical context. | Date | Event | Sentiment | Move | Catalyst | | Dec 03 | Earnings report | Positive | +8.1% | Reported FY2025 revenue growth and sharply reduced operating loss. | | Nov 25 | Growth ranking | Positive | +3.9% | Ranked 182nd on Deloitte Technology Fast 500 with 448% growth. | | Nov 21 | Earnings date notice | Neutral | -3.9% | Announced timing and access details for FY2025 results call. | | Nov 17 | Preliminary results | Positive | -33.2% | Shared preliminary FY2025 revenue and strong DSA growth metrics. | | Oct 21 | Conference participation | Neutral | -2.2% | Outlined participation in multiple November investor conferences. | Operationally positive news has sometimes aligned with gains but also seen sharp selloffs, indicating inconsistent market confidence in updates. Over the last few months, Inotiv reported improving FY2025 results with Q4 revenue of $138.1M and FY revenue of $513.0M, alongside a narrowed operating loss of $30.9M. Recognition on the 2025 Deloitte Technology Fast 500(TM) and strong DSA growth, with backlog around $138M, highlight expansion. However, preliminary results on Nov 17, 2025 coincided with a -33.2% move, contrasting with the later earnings-day gain of 8.13%. Today's AI partnership adds to a pattern of strategic initiatives amid volatile reactions. Regulatory & risk context. An effective S-3 shelf filed on 2025-08-29 allows future securities offerings, including an at-the-market equity program with up to 3.0% commission. The filing highlights an auditor's explanatory paragraph raising substantial doubt about going-concern status, material weaknesses in internal control, and warns of immediate dilution risk and variable ATM proceeds. Market pulse summary. This announcement details a strategic collaboration integrating VUGENE's AI-enabled bioinformatics platform into Inotiv's Discovery & Translational Sciences Division to better analyze complex epigenomic and proteomic data. It follows FY2025 revenue of $513.0M and recognition in the 2025 Deloitte Technology Fast 500(TM). Regulatory filings, including the 2025-08-29 S-3, highlight going-concern language, internal-control weaknesses, and dilution risk. Investors may watch how this AI partnership translates into Discovery and Safety Assessment growth and backlog trends.

Stock Titan
Dec 23rd, 2024
Inotiv Raises $24M in Equity Offering

Inotiv completed an equity offering, raising approximately $24 million by selling 6 million common shares at $4.25 each. The offering closed on December 19, 2024, with Lake Street Capital Markets as the sole book-running manager. An option allows underwriters to purchase up to 900,000 additional shares until January 17, 2025. The funds will be used for working capital, capital expenditures, and general corporate purposes to enhance financial flexibility and support strategic initiatives.

GlobeNewswire
Dec 18th, 2024
Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares

WEST LAFAYETTE, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization...